Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?-Reference-Cited by-同舟云学术

Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?

Published:2021-01-13 Issue:7 Volume:22 Page:923-935
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Fens Tanja¹²^ORCID,Zhou Guiling³,Postma Maarten J.¹²⁴⁵^ORCID,van Puijenbroek Eugène P.¹⁶⁷^ORCID,van Boven Job F.M.³⁸⁹^ORCID

Affiliation:

1. University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands

2. Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

3. Department of Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

4. University of Groningen, University Medical Center Groningen, Institute of Science in Healthy Aging & healthcaRE (SHARE), Groningen, The Netherlands

5. Faculty of Economics & Business, Department of Economics, Econometrics & Finance, University of Groningen, Groningen, The Netherlands

6. Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, MH, The Netherlands

7. Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

8. University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, The Netherlands

9. Medication Adherence Expertise Center of the Northern Netherlands (MAECON), Groningen, The Netherlands

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2021.1873953

Reference66 articles.

1. Global Initiative for Chronic Obstructive Lung Disease [Internet]. Global initiative for chronic obstructive lung disease - GOLD. [cited 2020 Sept 29]. Available from: https://goldcopd.org/

2. Chronic obstructive pulmonary disease (COPD). [cited 2020 Sept 29]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

3. WHO | COPD: Definition. WHO; [cited 2020 Sept 29]. Available from: https://www.who.int/respiratory/copd/definition/en/

4. Making sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economists

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncovering the action mechanism of Shenqi Tiaoshen formula ( (sic) (sic) (sic) (sic)(sic)) in the treatment of chronic obstructive pulmonary disease through network pharmacology, molecular docking, and experimental verification;J TRADIT CHIN MED;2024

2. Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany – The TriOptimize Study;International Journal of Chronic Obstructive Pulmonary Disease;2022-12

3. Effects of medication adherence on disease activity in chronic obstructive pulmonary disease: a systematic review and meta-analysis;Psychology, Health & Medicine;2022-11-07

4. Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review;Vaccines;2021-02-02